Cargando…
A Novel LMP1 Antibody Synergizes with Mitomycin C to Inhibit Nasopharyngeal Carcinoma Growth in Vivo Through Inducing Apoptosis and Downregulating Vascular Endothelial Growth Factor
Combined therapy emerges as an attractive strategy for cancer treatment. The aim of this study was to investigate the inhibitory effects of mitomycin C (MMC) combined with a novel antibody fragment (Fab) targeting latent membrane protein 1 (LMP1) on nasopharyngeal carcinoma (NPC) xenograft nude mice...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Molecular Diversity Preservation International (MDPI)
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3292017/ https://www.ncbi.nlm.nih.gov/pubmed/22408448 http://dx.doi.org/10.3390/ijms13022208 |
_version_ | 1782225218209579008 |
---|---|
author | Mao, Yuan Zhang, Da-Wei Wen, Juan Cao, Qing Chen, Ren-Jie Zhu, Jin Feng, Zhen-Qing |
author_facet | Mao, Yuan Zhang, Da-Wei Wen, Juan Cao, Qing Chen, Ren-Jie Zhu, Jin Feng, Zhen-Qing |
author_sort | Mao, Yuan |
collection | PubMed |
description | Combined therapy emerges as an attractive strategy for cancer treatment. The aim of this study was to investigate the inhibitory effects of mitomycin C (MMC) combined with a novel antibody fragment (Fab) targeting latent membrane protein 1 (LMP1) on nasopharyngeal carcinoma (NPC) xenograft nude mice. The inhibitory rates of MMC (2 mg/kg), Fab (4 mg/kg), MMC (2 mg/kg) + Fab (4 mg/kg), and MMC (1 mg/kg) + Fab (4 mg/kg) were 20.1%, 7.3%, 42.5% and 40.5%, respectively. Flow cytometry analysis showed that the apoptotic rate of xenograft tumor cells in the MMC and Fab combination group was 28 ± 4.12%, significantly higher than the MMC (2 mg/kg) group (P < 0.01). Immunohistochemical staining showed that VEGF expression in NPC xenografts was significantly inhibited in the combination group compared to the Fab (4 mg/kg) group (P < 0.05). In conclusion, both MMC and Fab could inhibit NPC xenograft tumor growth in vivo and combination therapy showed apparent synergistic anti-tumor effects, which may be due to the induction of tumor cell apoptosis and the downregulation of VEGF expression. These results suggest that the novel combined therapy utilizing traditional chemotherapeutics and antibody-targeted therapy could be a promising strategy for the treatment of NPC. |
format | Online Article Text |
id | pubmed-3292017 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Molecular Diversity Preservation International (MDPI) |
record_format | MEDLINE/PubMed |
spelling | pubmed-32920172012-03-09 A Novel LMP1 Antibody Synergizes with Mitomycin C to Inhibit Nasopharyngeal Carcinoma Growth in Vivo Through Inducing Apoptosis and Downregulating Vascular Endothelial Growth Factor Mao, Yuan Zhang, Da-Wei Wen, Juan Cao, Qing Chen, Ren-Jie Zhu, Jin Feng, Zhen-Qing Int J Mol Sci Article Combined therapy emerges as an attractive strategy for cancer treatment. The aim of this study was to investigate the inhibitory effects of mitomycin C (MMC) combined with a novel antibody fragment (Fab) targeting latent membrane protein 1 (LMP1) on nasopharyngeal carcinoma (NPC) xenograft nude mice. The inhibitory rates of MMC (2 mg/kg), Fab (4 mg/kg), MMC (2 mg/kg) + Fab (4 mg/kg), and MMC (1 mg/kg) + Fab (4 mg/kg) were 20.1%, 7.3%, 42.5% and 40.5%, respectively. Flow cytometry analysis showed that the apoptotic rate of xenograft tumor cells in the MMC and Fab combination group was 28 ± 4.12%, significantly higher than the MMC (2 mg/kg) group (P < 0.01). Immunohistochemical staining showed that VEGF expression in NPC xenografts was significantly inhibited in the combination group compared to the Fab (4 mg/kg) group (P < 0.05). In conclusion, both MMC and Fab could inhibit NPC xenograft tumor growth in vivo and combination therapy showed apparent synergistic anti-tumor effects, which may be due to the induction of tumor cell apoptosis and the downregulation of VEGF expression. These results suggest that the novel combined therapy utilizing traditional chemotherapeutics and antibody-targeted therapy could be a promising strategy for the treatment of NPC. Molecular Diversity Preservation International (MDPI) 2012-02-17 /pmc/articles/PMC3292017/ /pubmed/22408448 http://dx.doi.org/10.3390/ijms13022208 Text en © 2012 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0 This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Article Mao, Yuan Zhang, Da-Wei Wen, Juan Cao, Qing Chen, Ren-Jie Zhu, Jin Feng, Zhen-Qing A Novel LMP1 Antibody Synergizes with Mitomycin C to Inhibit Nasopharyngeal Carcinoma Growth in Vivo Through Inducing Apoptosis and Downregulating Vascular Endothelial Growth Factor |
title | A Novel LMP1 Antibody Synergizes with Mitomycin C to Inhibit Nasopharyngeal Carcinoma Growth in Vivo Through Inducing Apoptosis and Downregulating Vascular Endothelial Growth Factor |
title_full | A Novel LMP1 Antibody Synergizes with Mitomycin C to Inhibit Nasopharyngeal Carcinoma Growth in Vivo Through Inducing Apoptosis and Downregulating Vascular Endothelial Growth Factor |
title_fullStr | A Novel LMP1 Antibody Synergizes with Mitomycin C to Inhibit Nasopharyngeal Carcinoma Growth in Vivo Through Inducing Apoptosis and Downregulating Vascular Endothelial Growth Factor |
title_full_unstemmed | A Novel LMP1 Antibody Synergizes with Mitomycin C to Inhibit Nasopharyngeal Carcinoma Growth in Vivo Through Inducing Apoptosis and Downregulating Vascular Endothelial Growth Factor |
title_short | A Novel LMP1 Antibody Synergizes with Mitomycin C to Inhibit Nasopharyngeal Carcinoma Growth in Vivo Through Inducing Apoptosis and Downregulating Vascular Endothelial Growth Factor |
title_sort | novel lmp1 antibody synergizes with mitomycin c to inhibit nasopharyngeal carcinoma growth in vivo through inducing apoptosis and downregulating vascular endothelial growth factor |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3292017/ https://www.ncbi.nlm.nih.gov/pubmed/22408448 http://dx.doi.org/10.3390/ijms13022208 |
work_keys_str_mv | AT maoyuan anovellmp1antibodysynergizeswithmitomycinctoinhibitnasopharyngealcarcinomagrowthinvivothroughinducingapoptosisanddownregulatingvascularendothelialgrowthfactor AT zhangdawei anovellmp1antibodysynergizeswithmitomycinctoinhibitnasopharyngealcarcinomagrowthinvivothroughinducingapoptosisanddownregulatingvascularendothelialgrowthfactor AT wenjuan anovellmp1antibodysynergizeswithmitomycinctoinhibitnasopharyngealcarcinomagrowthinvivothroughinducingapoptosisanddownregulatingvascularendothelialgrowthfactor AT caoqing anovellmp1antibodysynergizeswithmitomycinctoinhibitnasopharyngealcarcinomagrowthinvivothroughinducingapoptosisanddownregulatingvascularendothelialgrowthfactor AT chenrenjie anovellmp1antibodysynergizeswithmitomycinctoinhibitnasopharyngealcarcinomagrowthinvivothroughinducingapoptosisanddownregulatingvascularendothelialgrowthfactor AT zhujin anovellmp1antibodysynergizeswithmitomycinctoinhibitnasopharyngealcarcinomagrowthinvivothroughinducingapoptosisanddownregulatingvascularendothelialgrowthfactor AT fengzhenqing anovellmp1antibodysynergizeswithmitomycinctoinhibitnasopharyngealcarcinomagrowthinvivothroughinducingapoptosisanddownregulatingvascularendothelialgrowthfactor AT maoyuan novellmp1antibodysynergizeswithmitomycinctoinhibitnasopharyngealcarcinomagrowthinvivothroughinducingapoptosisanddownregulatingvascularendothelialgrowthfactor AT zhangdawei novellmp1antibodysynergizeswithmitomycinctoinhibitnasopharyngealcarcinomagrowthinvivothroughinducingapoptosisanddownregulatingvascularendothelialgrowthfactor AT wenjuan novellmp1antibodysynergizeswithmitomycinctoinhibitnasopharyngealcarcinomagrowthinvivothroughinducingapoptosisanddownregulatingvascularendothelialgrowthfactor AT caoqing novellmp1antibodysynergizeswithmitomycinctoinhibitnasopharyngealcarcinomagrowthinvivothroughinducingapoptosisanddownregulatingvascularendothelialgrowthfactor AT chenrenjie novellmp1antibodysynergizeswithmitomycinctoinhibitnasopharyngealcarcinomagrowthinvivothroughinducingapoptosisanddownregulatingvascularendothelialgrowthfactor AT zhujin novellmp1antibodysynergizeswithmitomycinctoinhibitnasopharyngealcarcinomagrowthinvivothroughinducingapoptosisanddownregulatingvascularendothelialgrowthfactor AT fengzhenqing novellmp1antibodysynergizeswithmitomycinctoinhibitnasopharyngealcarcinomagrowthinvivothroughinducingapoptosisanddownregulatingvascularendothelialgrowthfactor |